A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies

Abstract Objectives Currently, there are two prognosis staging systems validated for transthyretin amyloidosis (ATTR). We sought to develop a new staging system dedicated to hereditary transthyretin amyloidosis (ATTRv) patients on specific treatments. Methods and Results A total of 258 patients diag...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Gabriela Neculae, Amira Zaroui, Robert Adam, Mounira Kharoubi, Benoit Funalot, Daniel Coriu, Ruxandra Jurcut, Thibaud Damy
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Oxford University Press 2025-12-01
coleção:	ESC Heart Failure
Assuntos:	amyloidosis ATTRv cardiomyopathy phenotype prognosis mortality
Acesso em linha:	https://doi.org/10.1002/ehf2.15414
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!